New Medicare rules could have a devastating effect on Amgen’s ( NASDAQ: AMGN ) anemia drug Epogen. The rules would combine payments for the services and drugs dialysis centers deliver to kidney-disease patients, in an effort to cut “overuse” of “profitable, separately billable drugs,” the Centers for Medicare and…

How badly does Sanofi-Aventis

When it comes to paying U.S. sales reps, GlaxoSmithKline ( NYSE: GSK )

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has reservations on approval by the U.S. Food and Drug Administration (FDA) of another version of enoxaparin sodium.

Original Source of Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium

Bloomberg is reporting that Genzyme has rejected Sanofi-Aventis’ offer for the company. Citing people familiar with the matter, the Wall Street Journal reported last Friday that the

FDA advisory panel members overwhelmingly rejected a plan to reduce the misuse and abuse of long-acting painkillers like OxyContin, saying they did not think it was strong enough to control the use of such prescription narcotics. Report

Original Source of FDA panel: Painkiller plan not strong enough

The FDA just gave Eisai a new weapon against generic competition for the company’s flagship Alzheimer’s

In the ongoing fight about sales rep overtime pay, chalk up a win for management. As BNet Pharma reports, reps at King Pharmaceuticals’ ( NYSE: KG ) Alpharma unit lost their bid to break out of the overtime exemption. The judge’s ruling brings the number of overtime cases decided…

Sound the alarm on Lovenox–generic competition is coming. The Sanofi-Aventis

The FDA is looking to higher-ups for help sorting out a potential conflict of interest on the recent Avandia advisory panel. After news emerged last week that one panelist, endocrinologist David Capuzzi, had been paid to speak on behalf of a GlaxoSmithKline ( NYSE: GSK ) product, agency officials…